S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Prologis Stock Leading U.S. Logistics Boom

Protagenic Therapeutics (PTIX) Competitors

$1.35
0.00 (0.00%)
(As of 04/17/2024 ET)

PTIX vs. PULM, ENVB, GRAY, MBIO, SHPH, SEEL, ADXS, XBIO, TRVN, and AKTX

Should you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Pulmatrix (PULM), Enveric Biosciences (ENVB), Graybug Vision (GRAY), Mustang Bio (MBIO), Shuttle Pharmaceuticals (SHPH), Seelos Therapeutics (SEEL), Ayala Pharmaceuticals (ADXS), Xenetic Biosciences (XBIO), Trevena (TRVN), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.

Protagenic Therapeutics vs.

Protagenic Therapeutics (NASDAQ:PTIX) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.

Pulmatrix received 196 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Protagenic TherapeuticsN/AN/A
PulmatrixOutperform Votes
196
52.55%
Underperform Votes
177
47.45%

Protagenic Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Protagenic Therapeutics has higher earnings, but lower revenue than Pulmatrix. Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagenic TherapeuticsN/AN/A-$5M-$1.15-1.17
Pulmatrix$7.30M1.05-$14.12M-$3.86-0.54

8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 3.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Protagenic Therapeutics had 2 more articles in the media than Pulmatrix. MarketBeat recorded 3 mentions for Protagenic Therapeutics and 1 mentions for Pulmatrix. Protagenic Therapeutics' average media sentiment score of 0.91 beat Pulmatrix's score of -0.50 indicating that Protagenic Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagenic Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pulmatrix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Pulmatrix has a consensus target price of $10.00, suggesting a potential upside of 378.47%. Given Pulmatrix's higher probable upside, analysts clearly believe Pulmatrix is more favorable than Protagenic Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagenic Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Pulmatrix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Protagenic Therapeutics has a net margin of 0.00% compared to Pulmatrix's net margin of -193.49%. Pulmatrix's return on equity of -63.94% beat Protagenic Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protagenic TherapeuticsN/A -101.81% -82.18%
Pulmatrix -193.49%-63.94%-40.88%

Summary

Pulmatrix beats Protagenic Therapeutics on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTIX vs. The Competition

MetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.99M$6.44B$4.78B$7.47B
Dividend YieldN/A3.13%2.98%3.99%
P/E Ratio-1.177.34182.7014.17
Price / SalesN/A309.072,530.7687.68
Price / CashN/A29.7046.9535.12
Price / Book1.635.334.624.19
Net Income-$5M$142.19M$102.17M$212.33M
7 Day Performance-17.68%-7.31%-4.74%-4.60%
1 Month Performance12.50%-6.31%-4.30%-3.16%
1 Year Performance-26.63%-3.14%10.36%4.59%

Protagenic Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PULM
Pulmatrix
1.143 of 5 stars
$1.92
+1.6%
$10.00
+420.8%
-30.3%$7.01M$7.30M-0.5028Analyst Report
Gap Up
ENVB
Enveric Biosciences
1.4633 of 5 stars
$0.94
+2.2%
$10.00
+962.5%
-45.2%$6.86MN/A-0.127Positive News
GRAY
Graybug Vision
0 of 5 stars
$4.33
+0.2%
N/A+4.5%$6.80MN/A-2.5027Gap Up
High Trading Volume
MBIO
Mustang Bio
1.8572 of 5 stars
$0.68
-1.4%
$17.25
+2,421.9%
-88.5%$7.11MN/A-0.1180Gap Up
SHPH
Shuttle Pharmaceuticals
0 of 5 stars
$0.42
flat
N/A-70.4%$7.12MN/A-0.997
SEEL
Seelos Therapeutics
1.5356 of 5 stars
$0.49
-3.9%
$70.00
+14,070.0%
-98.6%$6.76M$2.20M0.0015Gap Up
ADXS
Ayala Pharmaceuticals
0 of 5 stars
$0.67
+9.9%
N/A-47.9%$7.18M$3.24M0.00N/AAnalyst Report
Gap Up
XBIO
Xenetic Biosciences
0 of 5 stars
$4.72
+1.5%
$40.00
+747.5%
-19.1%$7.27M$2.54M-1.724Positive News
TRVN
Trevena
1.2889 of 5 stars
$0.40
-2.4%
$9.00
+2,148.3%
-46.9%$7.33M$3.12M-0.1335
AKTX
Akari Therapeutics
0 of 5 stars
$1.30
-7.1%
N/A-69.4%$7.35MN/A0.0015Analyst Report
Gap Up

Related Companies and Tools

This page (NASDAQ:PTIX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners